Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA6 | P23280 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | TPMT | P51580 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193886 | 0.91 | NPC1 (0.66) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10340049 | 0.90 | TSHR (0.63) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28103860 | 0.88 | TSHR (0.66) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Veratric Acid Methyl Ester SCHEMBL2050732 | 0.88 | MAPT (0.86) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Veratric Acid Methyl Ester SCHEMBL29573244 | 0.88 | MAPT (0.86) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8778631 | 0.88 | TSHR (0.70) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16174961 | 0.87 | TSHR (0.59) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28804913 | 0.84 | MAPT (0.56) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12538400 | 0.84 | TSHR (0.66) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7956486 | 0.84 | TSHR (0.66) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273819-A1 | THERMAL ENERGY STORAGE PHASE AND TEMPERATURE STABILIZATION CHANGE MATERIALS COMPRISING TRIAMINES AND METHODS FOR MAKING AND USING THEM | ENTROPY SOLUTIONS LLC (US) | 2018-09-27 | — | — | US | claimed |
| WO-2016179028-A1 | THERMAL ENERGY STORAGE PHASE AND TEMPERATURE STABILIZATION CHANGE MATERIALS AND METHODS FOR MAKING AND USING THEM | ENTROPY SOLUTIONS, LLC. (US) | 2016-11-10 | — | — | WO | claimed |
| CN-101104611-A | 3-methoxylflavonoid compound, preparation method and application thereof | ZHENGFENG YIN (CN) | 2008-01-16 | — | — | CN | claimed |
| WO-2025015175-A2 | HEATING, VENTILATION, AND AIR CONDITIONING (HVAC) SYSTEMS AND METHODS FOR USING SAME | STASIS ENERGY GROUP, LLC (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20180273819-A1 | THERMAL ENERGY STORAGE PHASE AND TEMPERATURE STABILIZATION CHANGE MATERIALS COMPRISING TRIAMINES AND METHODS FOR MAKING AND USING THEM | ENTROPY SOLUTIONS LLC (US) | 2018-09-27 | — | — | US | disclosed |
| WO-2016179028-A1 | THERMAL ENERGY STORAGE PHASE AND TEMPERATURE STABILIZATION CHANGE MATERIALS AND METHODS FOR MAKING AND USING THEM | ENTROPY SOLUTIONS, LLC. (US) | 2016-11-10 | — | — | WO | disclosed |
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | disclosed |
| EP-0972776-B1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | MITSUI CHEMICALS INC (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6153794-A | Phosphine sulfide, a manufacturing process therefor and use thereof | MITSUI CHEMICALS, INC. (JP) | 2000-11-28 | — | — | US | disclosed |
| CN-1262276-A | Phosphine sulfide preparing process and use thereof | MITSUI CHEMICALS INC (JP) | 2000-08-09 | — | — | CN | disclosed |
| EP-0972776-A1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | Mitsui Chemicals, Inc. (JP) | 2000-01-19 | — | — | EP | disclosed |
| US-6011063-A | Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | ESR2, ESR1, ESRRB | TSHR 774/4885CYP1A2 2411/4885CYP3A4 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.